New Allscripts (MDRX) CFO Won't Affect M&A Potential - Analyst
Tweet
Share
E-mailGet Alerts MDRX Hot Sheet
Price: $4.80 -7.34%
Rating Summary:
8 Buy, 19 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 5 | Down: 11 | New: 27
Rating Summary:
8 Buy, 19 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 5 | Down: 11 | New: 27
Join SI Premium – FREE
Allscripts (Nasdaq: MDRX) stock is lower Monday after announcing Richard J. Poulton will become its new CFO earlier. Some suspect that the new exec will try to stem the possibility of a merger.
One firm taking a different stance is Baird. Amid the new appointment, Baird said the potential for Allscripts to be acquired hasn't changed. In fact, Baird thinks the addition my be a modest positive for Allscipts if the firm decides to remain independent.
Allscripts recently disclosed receiving first-round bids from the likes of Carlyle, Blackstone, and others.
Shares are down 0.3 percent in afternoon trading.
One firm taking a different stance is Baird. Amid the new appointment, Baird said the potential for Allscripts to be acquired hasn't changed. In fact, Baird thinks the addition my be a modest positive for Allscipts if the firm decides to remain independent.
Allscripts recently disclosed receiving first-round bids from the likes of Carlyle, Blackstone, and others.
Shares are down 0.3 percent in afternoon trading.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA Securities Starts Dollarama Inc. (DOL:CN) (DLMAF) at Buy
- Enliven Therapeutics prices upsized public offering at $37.50 per share
- Baird Reiterates Outperform Rating on Oracle (ORCL)
Create E-mail Alert Related Categories
Analyst Comments, Management Changes, Mergers and AcquisitionsRelated Entities
Robert W BairdSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
